Evidence map›Paper›PMID 28460526›Full record

ArticleMolecular pharmaceutics2017

Cationic CaMKII Inhibiting Nanoparticles Prevent Allergic Asthma.

Angie S Morris, Sara C Sebag, John D Paschke, Amaraporn Wongrakpanich, Kareem Ebeid, Mark E Anderson, Isabella M Grumbach, Aliasger K Salem

Open access · greenAbstract read
In one paragraph

Article in Molecular pharmaceutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Recent Advances in Nanomaterials for Asthma Treatment.International journal of molecular sciences · 2022
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Angie S MorrisDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa , 115 South Grand Avenue, S228 PHAR, Iowa City, Iowa 52242, United States.
Sara C SebagDepartment of Internal Medicine, Carver College of Medicine, University of Iowa , 200 Hawkins Drive, Iowa City, Iowa 52242, United States.
John D PaschkeDepartment of Internal Medicine, Carver College of Medicine, University of Iowa , 200 Hawkins Drive, Iowa City, Iowa 52242, United States.
Amaraporn WongrakpanichDepartment of Pharmacy, Faculty of Pharmacy, Mahidol University , Bangkok 10400, Thailand.
Kareem EbeidDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa , 115 South Grand Avenue, S228 PHAR, Iowa City, Iowa 52242, United States.
Mark E AndersonDepartment of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland 21205, United States.
Isabella M GrumbachDepartment of Internal Medicine, Carver College of Medicine, University of Iowa , 200 Hawkins Drive, Iowa City, Iowa 52242, United States.
Aliasger K SalemDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa , 115 South Grand Avenue, S228 PHAR, Iowa City, Iowa 52242, United States.ORCID 0000-0002-1923-6633
University of Iowa · USJohns Hopkins University · USMahidol University · TH

Funding

Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5M
Mitochondrial Calmodulin Kinase II in Physiology and DiseaseR01HL070250 · NHLBI · VANDERBILT UNIVERSITY · PI ANDERSON, MARK E · 2002 to 2017
$5.2M
CaMKII in Sinus Node Physiology and DiseaseR01HL096652 · NHLBI · UNIVERSITY OF IOWA · PI ANDERSON, MARK E · 2009 to 2016
$3.0M
Immunomodulation Potential of Inhaled Engineered Nanomaterials as an Adverse Outcome PathwayU01ES027252 · NIEHS · UNIVERSITY OF IOWA · PI THORNE, PETER S · 2016 to 2020
$2.1M
Oxidized CaMKII in Atrial FibrillationR01HL113001 · NHLBI · UNIVERSITY OF IOWA · PI ANDERSON, MARK E · 2012 to 2016
$1.9M
NHLBI NIH HHS R01 HL070250NHLBI NIH HHS R01 HL096652NHLBI NIH HHS R01 HL113001NIEHS NIH HHS P30 ES005605NIEHS NIH HHS U01 ES027252
6 · The paper itself

Abstract

Asthma is a common lung disease affecting over 300 million people worldwide and is associated with increased reactive oxygen species, eosinophilic airway inflammation, bronchoconstriction, and mucus production. Targeting of novel therapeutic agents to the lungs of patients with asthma may improve efficacy of treatments and minimize side effects. We previously demonstrated that Ca

Indexed as

AnimalsAsthmaCalcium-Calmodulin-Dependent Protein Kinase Type 2Drug Delivery SystemsLactic AcidLungMiceNanoparticlesPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerCalcium-Calmodulin-Dependent Protein Kinase Type 2Lactic AcidPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerasthmaCaMKIINchitosannanoparticlePLGApoly(lactic-co-glycolic acid)

Identifiers

PMID28460526
PMCPMC5800301
OpenAlexW2610827450

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.